Acutis Names Abdel Halim, PharmD, MSc, PhD, DABCC, FAACC as Chief Scientific Officer
Abdel Halim PharmD, MSc, Ph.D., DABCC, FAACC has joined as Chief Scientific Officer and Executive Vice President for biopharma and diagnostics services.
Dr. Halim is a globally recognized expert in cancer molecular profiling, precision drug development, and diagnostic biomarker development with over 25 years of experience. One of only four laboratory scientists in the country to be triple board-certified, Dr. Halim is recognized by the medical community as well as regulators for his expertise and contributions to precision medicine and diagnostic development.
At Acutis, Dr. Halim will provide scientific leadership to advance clinical product development, cancer genomics and biopharma services. He has authored 65+ peer-reviewed articles, delivered 110 presentations and, most recently, published a single-author reference book on biomarkers, precision medicine and diagnostics in drug development.
Dr. Halim has led biomarker, diagnostic and precision medicine aspects in 150+ phase 1 to phase 3 clinical trials belonging to 40+ development programs with contributions to clinical trial design, conduct, analysis and interpretation. Over his career, he has served on 20+ CLSI committees to create clinical and laboratory guidelines; authored 12 of them. Dr. Halim is accredited by the FDA as a third-party reviewer of 510k submissions.